Company Filing History:
Years Active: 2010-2013
Title: Innovations of Apostolos Gittis in Anti-HIV and Anti-Cancer Research
Introduction
Apostolos Gittis is an accomplished inventor based in Baltimore, MD, known for his significant contributions to the field of medicinal chemistry. He has been instrumental in developing new compounds that show promise in the fight against HIV and cancer. With a total of two patents to his name, Gittis continues to push the boundaries of scientific research.
Latest Patents
Gittis's latest patents focus on heterocyclic and carbonate derivatives of nordihydroguaiaretic acid (NDGA) and their applications as new anti-HIV and anti-cancer agents. The innovative reactions he developed involve treating NDGA with various alkyl chlorides, 1-piperidinecarbonyl chloride, methyl chloroformate, or 1,1'-carbonyldiimidazole under alkaline conditions. This process yields corresponding phenol ethers, carbamates, and carbonates with impressive efficiency, achieving yields between 67-83%. Among these derivatives, nitrogen-containing compounds were converted into hydrochloride salts, which demonstrated good solubility and stability in aqueous solutions. Notably, these new compounds exhibited potent activities against HIV Tat-regulated transactivation in cos-7 cells. The most active transcription inhibitor from this series, compound 5b, has an IC of 0.88 µM.
Career Highlights
Apostolos Gittis is affiliated with The Johns Hopkins University, where he conducts his research and development work. His innovative approach and dedication to advancing medical science have made him a notable figure in his field.
Collaborations
Gittis has collaborated with esteemed colleagues, including Ru Chih C Huang and Evangelos Moudrianakis, to further enhance the impact of his research.
Conclusion
Apostolos Gittis's work in developing new anti-HIV and anti-cancer agents showcases his commitment to addressing critical health challenges through innovation. His contributions to medicinal chemistry are paving the way for future advancements in treatment options.